Song Hong, MD
Critical Care Medicine · Longview, TXNPI 1043311806
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $983 of the $1,554 with a category attached, or 63.3%. Olympus Corporation Of The Americas accounts for 70.2% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2019 at $1,215 and has fallen 98.1% since, to $24 in 2025.
Across 33 payments — averaging $47.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Olympus Corporation Of The Americas$1K
- Merck$131
- AstraZeneca$83
- Mylan Specialty L.p.$51
- Pulmonx Corporation$28
- Philips North America LLC$24
- plus $147 from 9 others
What the payments were for
- Travel & lodging$98363%
- Food & beverage$54335%
- Education$282%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Olympus Corporation Of The Americas | 10 | $1,090 |
| Merck | 2 | $131 |
| AstraZeneca | 5 | $83 |
| Mylan Specialty L.p. | 3 | $51 |
| Pulmonx Corporation | 1 | $28 |
| Philips North America LLC | 2 | $24 |
| Sunovion Pharmaceuticals Inc. | 2 | $22 |
| Abbott | 1 | $21 |
| Genentech USA, Inc. | 1 | $17 |
| Grifols USA, LLC | 1 | $17 |
| Insmed, Inc. | 1 | $16 |
| La Jolla Pharmaceutical Company | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Amgen | 1 | $13 |
| Travere Therapeutics, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,554 in reported general payments places this provider in the 70th percentile of 507 critical care medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 11 | $6,785 |
Paid to pharmacies, not to this prescriber.
Other critical care medicine in Longview
- Steven DavidoffPlano$364K
- William BartekAustin$284K
- Edwin ParsleyHouston$283K
- Hector PayanEl Paso$245K
- Bindu AkkantiHouston$185K
- Faisal MasudHouston$155K
- Sergio Trevino CastilloHouston$133K
- Akinyinka AjelabiKingwood$109K
- Anthony OrtegonDallas$106K
- Gary WeinsteinDallas$103K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.